These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8639764)

  • 21. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.
    Yoshida Y; Anzai N; Kawabata H; Kohsaka Y; Okuma M
    Ann Hematol; 1993 Apr; 66(4):175-80. PubMed ID: 8485205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.
    Casadevall N; Durieux P; Dubois S; Hemery F; Lepage E; Quarré MC; Damaj G; Giraudier S; Guerci A; Laurent G; Dombret H; Chomienne C; Ribrag V; Stamatoullas A; Marie JP; Vekhoff A; Maloisel F; Navarro R; Dreyfus F; Fenaux P
    Blood; 2004 Jul; 104(2):321-7. PubMed ID: 15054036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes.
    Ganser A; Seipelt G; Verbeek W; Ottmann OG; Maurer A; Kolbe K; Hess U; Elsner S; Reutzel R; Wörmann B
    Leukemia; 1994 Mar; 8(3):369-75. PubMed ID: 7510354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
    Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
    Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
    Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
    Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
    Ljung T; Bäck R; Hellström-Lindberg E
    Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
    Hansen PB; Johnsen HE; Hippe E; Hellström-Lindberg E; Ralfkiaer E
    Am J Hematol; 1993 Dec; 44(4):229-36. PubMed ID: 8237992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of recombinant human G-CSF combined with EPO in treatment of patients with MDS].
    Li ZY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):512-3. PubMed ID: 15972155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
    Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
    Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes.
    Runde V; Aul C; Ebert A; Grabenhorst U; Schneider W
    Eur J Haematol; 1995 Jan; 54(1):39-45. PubMed ID: 7859874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia.
    Bessho M; Jinnai I; Hirashima K; Saito M; Murohashi I; Ino H; Tsuji M; Fukuda M; Maruyama M; Kusumoto S
    Stem Cells; 1994 Nov; 12(6):604-15. PubMed ID: 7533579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome.
    Goy A; Belanger C; Casadevall N; Picard F; Guesnu M; Jaulmes D; Poisson D; Varet B
    Br J Haematol; 1993 Jun; 84(2):232-7. PubMed ID: 8398823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical efficacy analysis of recombinant human erythropoietin in the treatment of lower-risk myelodysplastic syndromes].
    Zhang H; Qin T; Xu Z; Fang L; Pan L; Hu N; Qu S; Zhang Y; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):18-23. PubMed ID: 24602726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
    Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
    Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.
    Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P;
    Br J Haematol; 2006 Jun; 133(5):513-9. PubMed ID: 16681638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes.
    Stasi R; Brunetti M; Terzoli E; Amadori S
    Blood; 2002 Mar; 99(5):1578-84. PubMed ID: 11861271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
    Chao NJ; Schriber JR; Long GD; Negrin RS; Catolico M; Brown BW; Miller LL; Blume KG
    Blood; 1994 May; 83(10):2823-8. PubMed ID: 7514046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.
    Jädersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit A; Cazzola M; Hellström-Lindberg E
    J Clin Oncol; 2008 Jul; 26(21):3607-13. PubMed ID: 18559873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis.
    Chen TL; Chiang YW; Lin GL; Chang HH; Lien TS; Sheh MH; Sun DS
    Stem Cell Res Ther; 2018 May; 9(1):119. PubMed ID: 29720275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.